The impact of the PAI-1 4G/5G polymorphism on the outcome of patients with ALI/ARDS

Thrombosis Research

Volumn 123, Issue 6, 2009, Pages 832-836

  Tsangaris, Iraklis ^a   Tsantes, Argiris ^a   Bonovas, Stefanos ^b   Lignos, Michalis ^a   Kopterides, Petros ^a   Gialeraki, Argiro ^a   Rapti, Evdoxia ^a   Orfanos, Stylianos ^a   Dimopoulou, Ioanna ^a   Travlou, Anthi ^a   Armaganidis, Apostolos ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b Hellenic Center for Disease Control and Prevention   (Greece)

Author keywords

ALI; ARDS; BAL; Fibrinolysis; Plasminogen activator inhibitor 1; Polymorphisms

Indexed keywords

D DIMER; GUANOSINE; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ACUTE LUNG INJURY; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ALLELE; ARTICLE; ASSISTED VENTILATION; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DISEASE SEVERITY; FEMALE; GENE DELETION; GENETIC ASSOCIATION; GENOTYPE; HOMOZYGOTE; HUMAN; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; VENTILATED PATIENT; VENTILATOR;

ACUTE LUNG INJURY; AGED; AGED, 80 AND OVER; ALLELES; BRONCHOALVEOLAR LAVAGE FLUID; FEMALE; GENOTYPE; HOMOZYGOTE; HUMANS; INDEL MUTATION; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; RESPIRATION, ARTIFICIAL; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 63249097461     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.07.018     Document Type: Article

References (40)

1. Ware L.B., and Matthay M.A. Medical progress: The acute respiratory distress syndrome. N Engl J Med 342 (2000) 1334-1349
2. Russell J.A. Genetics of coagulation factors in acute lung injury. Crit Care Med 31 (2003) S243-S247
3. Coughlin S.R. Thrombin signaling and protease-activated receptors. Nature 407 (2000) 258-264
4. Nawroth P.P., and Stern D.M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 163 (1986) 740-745
5. Gunther A., Mosavi P., Heinemann S., Ruppert C., Muth H., Markart P., et al. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 161 (2000) 454-462
6. Bertozzi P., Astedt B., Zenzius L., Lynch K., Le Maire F., Zapol W., et al. Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. N Engl J Med 322 (1990) 890-897
7. Idell S., Gonzalez K., Bradford H., Macarthur C.K., Fein A.M., Maunder R.J., et al. Procoagulant activity in bronchoalveolar lavage in the adult respiratory distress syndrome. Contribution of tissue factor associated with factor VII. Am Rev Respir Dis 136 (1987) 1466-1474
8. Idell S., James K.K., Levin E.G., Schwartz B.S., Manchanda N., Maunder R.J., et al. Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. J Clin Invest 84 (1989) 695-705
9. Idell S. Endothelium and disordered fibrin turnover in the injured lung: newly recognized pathways. Crit Care Med 30 Suppl 5 (2002) 274-280
10. Marshall B.G., Sageser D.S., Rao N.V., Emi M., and Hoidal J.R. Alveolar epithelial cell plasminogen activator. Characterization and regulation. J Biol Chem 265 (1990) 8198-8204
11. El Solh A.A., Bhora M., Pineda L., Aquilina A., Abbetessa L., and Berbary E. Alveolar plasminogen activator inhibitor-1 predicts ARDS in aspiration pneumonitis. Intensive Care Med 32 (2006) 110-115
12. Prabhakaran P., Ware L.B., White K.E., Cross M.T., Matthay M.A., and Olman M.A. Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. Am J Physiol Lung Cell Mol Physiol 285 (2003) L20-L28
13. Ware L.B., Matthay M.A., Parsons P.E., Thompson T., Januzzi J.L., and Eisner M.D. Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Crit Care Med 35 (2007) 1821-1828
14. Groeneveld A.N., Kindt I., Raijmakers P.G., Hack C.E., and Thijs L.G. Systemic coagulation and fibrinolysis in patients with or at risk for the adult respiratory distress syndrome. Thromb Haemost 78 (1997) 1444-1449
15. Dawson S., Wiman B., Hamsten A., Green F., Humphries S., and Henney A.M. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 268 (1993) 10739-10745
16. Festa A., D' Agostino Jr. R., Rich S.S., Jenny N.S., Tracy R.P., and Haffner S.M. Promoter (4G/5G) plasminogen activator inhibitor -1 genotype and plasminogen activator inhibitor -1 levels in blacks, Hispanics and non-Hispanics whites: the Insulin Resistance Atherosclerosis Study. Circulation 107 (2003) 2422-2427
17. Lane D.A., and Grant P.J. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 95 (2000) 1517-1532
18. Hoekstra T., Geleijnse J.M., Schouten E.G., and Kluft C. Plasminogen activator inhibitor - type 1: its plasma determinants and relation with cardiovascular risk. Thromb Haemost 91 (2004) 861-872
19. Bernard G.R., Artigas A., Brigham K.L., Carlet J., Falke K., Hudson L., et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 149 (1994) 818-824
20. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 342 (2000) 1301-1308
21. Eisner M.D., Thompson T., Hudson L.D., Luce J.M., Hayden D., Schoenfeld D., et al. Acute Respiratory Distress Syndrome Network. Efficacy of low tidal volume ventilation in patients with different clinical risk factors for acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med 164 (2001) 231-236
22. Komitopoulou A., Platokouki H., Kapsimali Z., Pergantou H., Adamtziki E., and Aronis S. Mutations and polymorphisms in genes affecting hemostasis proteins and homocysteine metabolism in children with arterial ischemic stroke. Cerebrovasc Dis 22 (2006) 13-20
23. Eriksson P., Kallin B., van't Hooft F.M., Bavenholm P., and Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 92 (1995) 1851-1855
24. McCormack L.J., Semple J.I., Stickland M.H., Barrett J.H., and Grant P.J. The effect of number of days in culture and plasminogen activator inhibitor -1 (PAI-1) 4G/5G genotype on PAI-1 antigen release by cultured human umbilical vein endothelial cells. Thromb Res 92 (1998) 199-206
25. Gray R.P., Yudkin J.S., and Patterson D.L. Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction: a role for plasminogen activator inhibitor?. Br Heart J 70 (1993) 530-536
26. Mellbring G., Dahlgren S., and Wiman B. Plasma fibrinolytic activity in patients undergoing major abdominal surgery. Acta Chir Scand 151 (1985) 109-112
27. Pralong G., Calandra T., Glauser M.P., Schellekens J., Verhoef J., Bachmann F., et al. Plasminogen activator inhibitor type 1: a new prognostic marker in septic shock. Thromb Haemost 61 (1989) 459-462
28. Colucci M., Paramo J.A., and Collen D. Generation in plasma of a fast acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 75 (1985) 818-824
29. Sapru A., Wiemels J.L., Witte J.S., Ware L.B., and Matthay M.A. Acute lung injury and the coagulation pathway: potential role of gene polymorphisms in the protein C and fibrinolytic pathways. Intensive Care Med 32 (2006) 1293-1303
30. Hermans P.W., Hibberd M.L., Booy R., Daramola O., Hazelz et J.A., de Groot R., et al. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group. Lancet 354 (1999) 556-560
31. Geishofer G., Binder A., Müller M., Zöhrer B., Resch B., Müller W., et al. Central European Meningococcal Genetic Study Group. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene in children with systemic meningococcaemia. Eur J Pediatr 164 (2005) 486-490
32. Haralambous E., Hibberd M.L., Hermans P.W., Ninis N., Nadel S., and Levin M. Role of functional plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism in susceptibility, severity and outcome of meningococcal disease in Caucasian children. Crit Care Med 31 (2003) 2788-2793
33. Menges T., Hermans P.W., Little S.G., Langefeld T., Boning O., Engel J., et al. Plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism and prognosis of severely injured patients. Lancet 357 (2001) 1096-1097
34. Garcia-Seggara G., Espinosa G., Tassies D., Oriola J., Aibar J., Bove A., et al. Increased mortality in septic shock with the 4G/4G genotype of plasminogen activator inhibitor 1 in patients of white descent. Intensive Care Med 33 (2007) 1354-1362
35. Dahlem P., Bos A.P., Haitsma J.J., Schultz M.J., Meijers J.C.M., and Lachmann B. Alveolar fibrinolytic capacity suppressed by injurious mechanical ventilation. Intensive Care Med 31 (2005) 724-732
36. Choi G., Wolthuis E.K., Bresser P., Levi M., van der Poll T., Dzoljic M., et al. Mechanical ventilation with lower tidal volumes and positive end expiratory pressure prevents alveolar coagulation in patients without lung injury. Anesthesiology 105 (2006) 689-695
37. Panahloo A., Mohamed-Ali V., Gray R.P., Humphries S.E., and Yudkin J.S. Plasminogen activator inhibitor-1 (PAI-1) activity post myocardial infarction: the role of acute phase reactants, insulin-like molecules and promoter (4G/5G) polymorphism in the PAI-1 gene. Atherosclerosis 168 (2003) 297-304
38. Catto A.J., Carter A.M., Stickland M., Bamford J.M., Davies J.A., and Grant P.J. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease. Thrombosis and Haemostasis 77 (1997) 730-734
39. Jood K., Ladenvall P., Tjarnlund-Wolf A., Ladenvall C., Andersson M., Nilsson S., et al. Fibrinolytic gene polymorphism and ischemic stroke. Stroke 36 (2005) 2077-2081
40. A.E. Tsantes, G.K. Nikolopoulos, P.G. Bagos, S. Bonovas, P. Kopterides, and G. Vaiopoulos. The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk. Thromb Res (2008), doi:10.1016/j.thromres.2007.09.005.